Celularity secures strategic license deal worth up to $35M for biomaterials portfolio
Source: SeekingAlpha
2026-03-10 08:45:12 ET
More on Celularity
Read the full article on Seeking Alpha
For further details see:
Celularity secures strategic license deal worth up to $35M for biomaterials portfolio
Celularity Inc.
NASDAQ: CELU
CELU Trading
-1.48% G/L:
$1.33 Last:
85,034 Volume:
$1.24 Open:
CELU Latest News
March 12, 2026 08:45:00 am
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
March 12, 2026 08:30:00 am
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
CELU Stock Data
$36,623,989
16,924,239
4.59%
22
N/A
Biotechnology & Life Sciences
Healthcare
US
Florham Park
